Rare Mutations of \textit{CACNB2} Found in Autism Spectrum Disease-Affected Families Alter Calcium Channel Function

Alexandra F. S. Breitenkamp\textsuperscript{1}, Jan Matthes\textsuperscript{1}, Robert Daniel Nass\textsuperscript{1}, Judith Sinzig\textsuperscript{2,3}, Gerd Lehmkuhl\textsuperscript{3}, Peter Nürnberg\textsuperscript{4}, Stefan Herzig\textsuperscript{1,5}\textsuperscript{*}

\textsuperscript{1}Department of Pharmacology, University of Cologne, Cologne, Germany, \textsuperscript{2}Department of Child and Adolescent Psychiatry and Psychotherapy, LVR-Klinik Bonn, Bonn, Germany, \textsuperscript{3}Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany, \textsuperscript{4}Cologne Center for Genomics, University of Cologne, Cologne, Germany, \textsuperscript{5}Center for Molecular Medicine, University of Cologne, Cologne, Germany

Abstract

Autism Spectrum Disorders (ASD) are complex neurodevelopmental diseases clinically defined by dysfunction of social interaction. Dysregulation of cellular calcium homeostasis might be involved in ASD pathogenesis, and genes coding for the L-type calcium channel subunits \textit{Ca}_{\text{a1.2}} (\textit{CACNA1C}) and \textit{Ca}_{\text{a1.2}} (\textit{CACNB2}) were recently identified as risk loci for psychiatric diseases. Here, we present three rare missense mutations of \textit{CACNB2} (G167S, S197F, and F240L) found in ASD-affected families, two of them described here for the first time (G167S and F240L). All these mutations affect highly conserved regions while being absent in a sample of ethnically matched controls. We suggest the mutations to be of physiological relevance since they modulate whole-cell \textit{Ba}\textsuperscript{2+} currents through calcium channels when expressed in a recombinant system (HEK-293 cells). Two mutations displayed significantly decelerated time-dependent inactivation as well as increased sensitivity of voltage-dependent inactivation. In contrast, the third mutation (F240L) showed significantly accelerated time-dependent inactivation. By altering the kinetic parameters, the mutations are reminiscent of the \textit{CACNA1C} mutation causing Timothy Syndrome, a Mendelian disease presenting with ASD. In conclusion, the results of our first-time biophysical characterization of these three rare \textit{CACNB2} missense mutations identified in ASD patients support the hypothesis that calcium channel dysfunction may contribute to autism.

Citation: Breitenkamp AFS, Matthes J, Nass RD, Sinzig J, Lehmkuhl G, et al. (2014) Rare Mutations of \textit{CACNB2} Found in Autism Spectrum Disease-Affected Families Alter Calcium Channel Function. PLoS ONE 9(4): e95579. doi:10.1371/journal.pone.0095579

Editor: Michael Edward Zwick, Emory University School Of Medicine, United States of America

Received October 25, 2013; Accepted March 27, 2014; Published April 21, 2014

Copyright: © 2014 Breitenkamp et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the “Koeln Fortune” program (KF 20/2006 and KF 93/2007) and DFG, the German Research Foundation, (He 1578 15-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: stefan.herzig@uni-koeln.de

Introduction

Autism spectrum disorder (ASD) is defined by dysfunction of social interaction and communication, stereotypic behavior and sensory integration problems. It is a complex neuro-developmental disease, which might result from an altered brain ontogenesis or altered neural homeostasis. According to the Centers for Disease Control and Prevention (CDC) the prevalence of ASD in the US population is 1:88 [1]. Until now, genetic explanations for ASD are limited to rare chromosomal abnormalities like copy number variations or very rare single gene disorders. A first hint to unravel pathophysiological pathway of ASD came from the identification of the mutation p.G406R found in the L-type calcium channel pore-forming subunit \textit{Ca}_{\text{a1.2}} (\textit{CACNA1C}) in patients with Timothy Syndrome (TS) [2]. Whole-cell patch clamp recordings showed that the TS-mutation leads to a decelerated and incomplete inactivation of the calcium inward current. The phenotype of TS demonstrates the consequences of inadequate inactivation behavior of voltage gated calcium channels (VGCC) in different biological contexts, like heart, brain, and the immune system. Calcium channel inactivation is a key mechanism by which cells are able to tightly control intracellular calcium levels and therefore the activity of excitable cells. Of note, calcium channel inactivation is not exclusively controlled by the channel pore, but also depends on auxiliary subunits, namely \textit{Ca}_{\text{a1.2}} and \textit{Ca}_{\text{a1.2}} [3,4]. The assembly of the subunits and their specific isoforms determines the distinctive behavior of VGCCs for the neuronal function. The number of permutations of calcium channel complexes with their subunits, isoforms and splice-variants paves the way for fine-tuned calcium channel function adapted for information processing. There are transcripts of ten pore-forming \textit{Ca}_{\text{a1.2}}-subunit genes (\textit{CACNA1A} to \textit{CACNA1I} and \textit{CACNB1}), which undergo extensive alternative splicing and in concert with auxiliary subunits exhibit different biophysical properties and expression profiles as well as distinct subcellular targeting [3].

Particularly \textit{Ca}_{\text{a1.2}}-subunits have been shown to impact surface expression and modulation of channel activity and kinetics, leading to an increased L-type calcium channel activity, as revealed in whole-cell [6,7] and single-channel recordings [8]. A wide variation of inactivation behavior has been described for the splice variants of the \textit{B2}-subunit [4]. Even slight structural differences within the \textit{Ca}_{\text{a1.2}}-subunit can strongly modify the gating behavior of L-type calcium channels [8–10]. Interestingly,
the expression of distinct CaVβ-subunits within the brain is dependent on the stage of neuronal development [11]. Since the discovery of the TS-mutation and its effect on inactivation of the L-type calcium channel, additional calcium channel genes or loci have been associated with ASD, e.g. the genes for the pore-forming subunits CACNA1D [12], CACNA1F [13], CACNA1G [14], CACNA1H [15] and the auxiliary subunit CACNB1 [14]. These studies emphasize the importance of calcium channel activity, inactivation and calcium signaling in a broader sense for the pathophysiology of ASD. Interestingly, the activity and kinetics of several pore-forming subunits of L-type (CaV1.1–1.4) and Non-L-type (CaV2.1–2.3) channels [2,12,13,16] are regulated by CaVβ-subunits. Moreover, they are involved in various signaling pathways [2,17,18], all of which have been linked to ASD pathophysiology previously. Nevertheless, studies considering the role of calcium channels in ASD have focused on the pore-forming subunits of the calcium channel complex, even though gene clusters of interacting proteins participating in linear signaling pathways would have a similar chance of being involved in the etiology of ASD [19].

Based on our previous studies showing that current and gating kinetics profoundly depend on the particular CaVβ-subunit isoform or splice variant associated with the channel pore [8,9], we hypothesized that CaVβ-subunit mutations might lead to electrophysiological phenotypes similar to that observed in TS. Though all four CaVβ-subunit genes (CACNB1–CACNB4) are expressed within the brain [20] we chose CACNB2 because of positional evidence from a meta-analysis of linkage data [21]. Here, Trikalinos and colleagues showed genome-wide suggestive significance for a designated bin 10p12–q11.1, which embraces a large genomic region including the CACNB2 gene in autistic siblings. Recently, CACNB2 was found as a risk locus for five major psychiatric disorders including ASD [22] and thus is regarded as a susceptibility gene.

In our current study, we searched for mutations in the β2-subunit gene that might affect gating behavior of voltage-dependent calcium channels. In a mutation screening, 155 patients with ASD were sequenced and the results were filtered for most promising candidates. We included only missense variants, which were not present in our cohort of 259 matched controls and located in highly conserved regions of the protein as an indicator of functional importance. Furthermore, the mutations had to be unknown or potentially damaging according to in-silico predictions.

Here, for the first time, we present three missense mutations located in conserved regions of the calcium channel CACNB2 gene found in three families affected by ASD. In electrophysiological analyses of recombinant channels, these missense mutations were found to differentially alter current kinetics. Though our data do not prove an association between these CACNB2 mutations and ASD, our findings support the idea of Cavβ2 variants being of functional relevance for ASD pathophysiology.

**Materials and Methods**

**Ethics Statement**

Procedures were approved by the Institutional Review Board (application number 04-223) of the medical faculty of the University of Cologne.

**Subjects**

gDNA samples were available from 259 healthy controls and 155 patients with Autistic Spectrum Disorder (ASD), each are ethnically matched groups of Caucasians of west-European origin. The cases were elicited from three different sources: Twenty patients were recruited by the Department of Child & Adolescent Psychiatry and Psychotherapy, University of Cologne. These patients meet diagnostic criteria for ‘broad ASD’ (e.g. Asperger’s) based on interview for DSM-IV-R. A written informed consent was obtained from the parents or legal guardians of the minors using the consent form approved by the I.R.B. of the University of Cologne (Germany). Ten cases were included from Autism Tissue Program (www.aptportal.org) from the Maryland National Institute of Child Health and Human Development (NICHD) Brain Tissue Center and the Harvard Brain Tissue Resource Center (USA), published e.g. in [23]. 125 cases were provided by the Autism Genetic Resource Exchange (AGRE) Consortium (http://research.agre.org/program/descr.cfm). All AGRE-Patients met diagnosis for ‘autism’ and each family was ascertained on the condition that at least two individuals were diagnosed with ASD [24], where diagnostic tests included autism diagnostic interview-revised (ADI-R) [25] and the autism diagnostic observational schedule (ADOS) [26]. Regulatory review, approval, and oversight of AGRE’s human subject research is provided by Western IRB (title: AUTISMGENETICRESOURCES). In order to find new sequence variations with a putative function-altering effect, all exons and their flanking intronic sequences of CACNB2 were sequenced in 155 ASD patients. The number of sequenced cases enabled the detection of rare SNPs (f = 0.01) with a probability of 96% to detect it once and 81% to detect it twice. The power calculation was made according to Glatt et al. [27]. To assure a strong genetic background, patients from multiplex families with a severe phenotype were selected.

**Figure 1. Splice scheme of human CACNB2 resulting in 9 splice variants of the Caβ2-subunit with the localization of the three mutations.** Spliced exons are shown in light grey and conserved exons in dark grey. All nine splice variants express the mutation-carrying exon 5, while three of variants contain the localization of the third mutation in exon 7c [10].

doi:10.1371/journal.pone.0095579.g001
Table 1. Clinical Features of ASD patients with rare mutations in CACNB2.

| Description                  | Patient 1 (AU062603) | Patient 2 (AU1338304) | Patient 3 (AU066204) |
|------------------------------|----------------------|-----------------------|----------------------|
| Mutations                    | c.334G>A             | c.425C>T              | c.553T>C             |
| Genotype                     | ++                   | ++                    | ++                   |
| Gender                       | M                    | M                     | F                    |
| Epilepsy                     | Yes                  | Unknown               | No                   |
| Type                         | Complex partial      |                       |                      |
| **Autism**                   |                      |                       |                      |
| ADI-R                        | Autism               | Autism                | Autism               |
| ADOS                         | Autism               | Autism                | Autism               |
| Brain Imaging                |                      |                       |                      |
| MRI                          | normal               | Unknown               | Normal               |

ADI-R, Autism Diagnostic Interview-Revised; ADOS, Diagnostic Observation Schedule-Generic; MRI, magnetic resonance imaging.

doi:10.1371/journal.pone.0095579.t001

The control group consisting of 259 matching controls was kindly provided by Dr. Heusch and Dr. Brodde, published in [28]. Based on the gender-dependent frequency of ASD [1], we chose an appropriate male to female ratio for both groups of about 5:1.

Genotypic and DNA Sequence Analyses

Oligonucleotides to all known exons of the CACNB2 gene were designed according to genomic sequences found in the Celera data base using Primer3. PCR amplification of DNA samples was carried out with GoTaq (Promega) according to the manufacturer’s protocol; annealing temperature was chosen according to Primer3. Mutational analyses were carried out with Mutation Surveyor. PCR fragments were purified using ExoI and SAP (NEB), and sequencing was performed with an ABI 3730 automated DNA sequencer.

DNA Constructs and Site-directed Mutagenesis

For functional analysis, mutations p.G167S and p.S197F were introduced in human β2c cDNA (NM_201596.2) and the mutation p.F240L was introduced in β3L,E7c (NM_201597.2) by site-directed mutagenesis (Stratagene QuikChange Kit) and verified by sequencing.

EGFP was used as reporter gene, which was coexpressed together with the β2-subunit by the bicistronic pIRES2-EGFP vector (Clontech). G167S forward primer 5’-gataagggagattgtaaaagaagatggaataccgatc-3’; G167S reverse primer 5’-gaatcggatttcacagctttcttt- ttaaagcctgttcttt-3’; S197F forward primer 5’-cagagagccagcaagggaaattctcgaacacag- 3’; S197F reverse primer 5’-gatagggcgattggtaaaagaaagctgtt- gct-3’; F240L forward primer 5’-ggatgatgaatttcctcctgatttactgaagtagaatttcccttgcttggctctc- 3’; F240L reverse primer 5’-gatagggcgattggtaaaagaaagctgttgctc-3’. DNA Constructs and Site-directed Mutagenesis were performed using ExoI and SAP (NEB) and sequencing was performed with an ABI 3730 automated DNA sequencer.

Cell Culture

In brief, HEK-293β1c cells stably expressing Ca2+1.2 subunit (GeneBank accession #NM_000719) cloned from human heart [29] were grown in Petri dishes in Dulbeccos modified Eagle medium (PAA, Germany) supplemented with 10% FBS (PAA, Germany), penicillin (10 U/ml), and streptomycin (10 μg/ml; PAA, Germany). Cells were selected by geneticin (G418) (PAA, Germany) at a final concentration of 500 μg/ml. Cells were routinely passaged twice a week and incubated at 37°C under 6% CO2 growth conditions. HEK-293 β1c cells were transfected using SuperFect reagent (Qiagen). For whole-cell recordings, cells were transfected with a 2:3 ratio of either human WT or mutant β2c- subunit and human α2δ1-subunit [30].

Electrophysiology

Whole-cell recordings in EGFP-positive cells were obtained 48–72 h after transfection. Immediately prior to recording, cells kept in 35-mm culture dishes were washed at room temperature (19–23°C) with bath solution. For constructs based on human β2c cDNA (NM_201596.2) the bath solution contained (in mM) 20 BaCl2, 1 MgCl2, 10 HEPES, 40 TEA-Cl, 10 dextrose, and 65 CsCl (pH 7.2 with TEA-OH) and pipette solution (in mM) 105 CsCl, 25 TEA-Cl, 11 EGTA, and 10 HEPES (pH 7.2 with CsOH). Holding potential was −100 mV. For constructs based on human β2d,E7c cDNA (NM_201597.2) the bath solution contained (in mM) 5 BaCl2, 1 MgCl2, 10 HEPES, 40 TEA-Cl, 10 dextrose, and 92 CsCl (pH 7.2 with TEA-OH). Patch pipettes made from borosilicate glass (1.7 mm diameter and 0.283 mm wall thickness, Hilgenberg GmbH, Malsfeld, Germany) were polished using a Narishige MF-83 microforge (Narishige Scientific Instruments, Foster City, CA, USA). Voltage dependence of Ba2+ conductance was determined by a two-pulse protocol. For β2d,E7c cDNA (NM_201597.2) the conditioning first pulse (stepped from −100 mV to +10 mV) was held for 5 s and the second pulse (of +10 mV) for 10 s. For β2d,E7c cDNA (NM_201597.2) the conditioning first pulse was stepped from −75 mV to +5 mV for 1 s and the second pulse (of +10 mV) was held for 125 ms. For both steady-state inactivation protocols the relative magnitude of inward current elicited during the second pulse was plotted as a function of the voltage of the conditioning first pulse.

Data were analyzed using pCLAMP6 (Axon Instruments) and GraphPad 5 Prism. Currents were filtered at 2 kHz. Data were fitted to a Boltzmann function to obtain the half point (V0.5) and...
slope factor (dV) for the voltage dependence of inactivation; Fits were performed after subtracting the offset from the peak values of the steady-state inactivation data. Offset was defined as a deviation from zero at the end of a fully inactivating current (after a 5000ms prepulse followed by a 125ms test pulse at +10mV). For voltage dependence of activation data were fitted by combined Ohm and Boltzmann relation $I(V) = \frac{G_{\text{max}}(V - V_R)}{1 + \exp\left(\frac{V - V_0}{C_1}\right)}$ according to [31].

Statistical Analysis

Student’s unpaired two-tailed t-test (GraphPad Prism 5, GraphPad Software, San Diego, CA) was used to compare electrophysiological parameters gained with the several CACNB2 mutations and their corresponding wildtypes. $P<0.05$ was considered significant. All p-values are listed in table S2. Data are presented as mean ± SEM.

Results

We performed a screening for mutations in CACNB2 by sequencing all 19 exons and their flanking intronic regions from 155 patients with ASD. All variants found are listed in table S1. We filtered for variants causing non-synonymous substitutions, frameshifts, or splice site changes and identified six missense mutations. Since two of them occurred at similar frequencies in our patient cohort, our control cohort, and the NCBI database of short genetic variations (dbSNP), they were not further considered. One substitution (“New11” in tabl S1.) is likely to be benign according to the prediction of polymorphism phenotyping tool (PolyPhen2); also the amino acid exchange of the minor allele is prevalent in other species (data not shown). Three non-synonymous mutations were located in conserved domains of the protein (Fig. 1) and subsequently analyzed for functional effects. They were detected in three different patients who all were heterozygous
carriers (Fig. 2a). The mutations were absent from 259 healthy controls.

Patient 1 showed a variation at cDNA position 334 from guanine to adenine resulting in an amino acid exchange from glycine to serine (p.G167S, referring to NM_201596.2). The substitution is not annotated in dbSNP and according to the PolyPhen2 prediction ‘probably damaging’ for the CaV2 function. Patient 2 had the cytosine at position 425 changed to thymine resulting in a substitution of phenylalanine for serine (p.S197F). This mutation is an annotated rare variant and shows a ‘possibly damaging’ PolyPhen2 score. The third affected patient had the transition c.T553C which results in a phenylalanine-to-leucine change (p.F240L, referring to NM_201597.2). The missense mutation is not annotated and PolyPhen2 predicts a ‘benign’ phenotyping score. The mutations p.G167S and p.S197F were found by analyzing the fifth exon, which is expressed in all splice isoforms; p.F240L was found in the alternative exon 7c (nomenclature according to Foell et al. [32]). All patients were diagnosed with autism by both ADI-R and ADOS. The clinical features of the patients are compiled in Table 1.

The subsequently performed cosegregation analysis showed a low penetrance. Two variants showed incomplete segregation since some siblings, who were not obviously affected, were carriers of the mutation (Fig. 2b). Since complex-genetic disorders manifest depending on multiple factors, a low penetrance and incomplete cosegregation can be expected. In the literature, it has been suggested that pathogenic variants might be masked by epigenetic marks and thus are less penetrant [33] or that pathogenic variants follow an oligogenic pattern of inheritance, resulting in more severe or different phenotypes or are modified by the presence of additional variants [34]. Accordingly, unaffected carriers of a mutation might be possibly influenced by unknown genetic and epigenetic mechanisms [35] or might be subclinically affected.

As members of the membrane-associated guanylate kinase (MAGUK) protein family [8–10], β-subunits are comprised of two highly conserved central (GK and SH3) domains, flanked and interspersed by more variable N- and C-termini and a central HOOK domain (Fig. 1). The β2-subunit is subject to extensive alternative splicing of the N-terminus and within the central HOOK domain, comprising the alternative exons 7a-c (Fig. 1) [36]. All three mutations are located within the HOOK domain (Fig. 1), which is known to modulate calcium channel inactivation [37,38]. The wildtype sequence of all three missense mutations followed full conservation across species (Fig. 2c) indicating functional relevance.

To investigate the effect of the mutations on calcium channel function, we heterologously expressed WT and mutant forms of the human β2 together with human α2δ1 and EGFP in HEK-293 cells stably expressing a human CaV1.2 pore-forming subunit, followed by whole-cell patch-clamp recordings. There are nine splice-variants of CaV2β, with different inactivation kinetics [4]. The mutations p.G167S and p.S197F are present in all these CaV2β splice forms, and there is no predominant splice form in the brain. In accordance with our hypothesis and deductions from the TS-channel model, we expect a reduction of the channels inactivation rate. To evaluate this effect in the mutations we performed whole-cell experiments using Ba2⁺ as charge carrier, since the TS-mutation selectively decelerates time-dependent inactivation and spares or even accelerates calcium-dependent inactivation [39]. For the quantification of mutants’ influence on channel inactivation behavior we chose the β2d splice variant as a suitable reference isoform, because of its relatively fast inactivation kinetics [4,8]. We compared the WT with the mutations p.G167S and p.S197F and the mutation p.F240L was analyzed separately with an appropriate WTE7c including its alternative exon 7c. The respective splice forms β2d_G167S and β2d_S197F were compared with their respective WT; N = 9 and β2dE7c_WT: N = 5.

Peak current densities tended to be enhanced in the mutants β2d_G167S and β2d_S197F compared to β2d_WT. These mutations also caused a slight, non-significant shift of the I-V relationships towards more positive test potentials (Fig. 3a). Conversely, for the mutation of the β2dE7c_WT (β2dE7c_F240L), the I-V relationship revealed a trend towards enhanced channel activity at negative test potentials (Fig. 3b).

Steady-state inactivation was examined using two-pulse protocols. Data and Boltzmann fits are depicted in Fig. 4a and 4b. The voltage of half-maximal inactivation (V0.5_max) did not differ significantly between the three mutant channel complexes and their respective controls (Fig. 4c). However, a significant flattening of the Boltzmann curves was observed for β2d_G167S and β2d_S197F.
\(\beta_{2d\_S197F}\), as indicated by the slope factor \(dV\) (Fig. 4d). Numeric values are compiled in Table 2.

As described previously for the Timothy Syndrome, the most notable differences between mutants and WT were observed in the time course of whole-cell \(\text{Ba}^{2+}\) currents. The mutant \(\beta_{2d\_G167S}\) and \(\beta_{2d\_S197F}\) subunit induced a decelerated time-dependent inactivation of the channel complex within a 150ms test pulse (Fig. 5a). The WT with the alternative exon 7c inactivated more slowly than the WT with exon 7a. It was therefore examined using an extended test pulse duration (see scale bars in Fig. 5a). Compared with the adequate \(\beta_{2d\_7c\_WT}\) the mutant \(\beta_{2d\_E7c\_F240L}\) showed an accelerated time-dependent inactivation. The mutants and the WT with Exon 7a were recorded with 20mM \(\text{Ba}^{2+}\) (compare [9]) and those with exon 7c were recorded with 5mM \(\text{Ba}^{2+}\) because of insufficient voltage-control with 20mM \(\text{Ba}^{2+}\) and prolonged test pulse protocols (500ms). We analyzed the extent of time-dependent inactivation as the percentage of current that has inactivated after 150ms of depolarization (% inactivation). As expected from the representative whole-cell current traces, the currents inactivated significantly more slowly for all test potentials in case of \(\beta_{2d\_S197F}\) and at 20mV in case of \(\beta_{2d\_G167S}\) (Fig. 5b). In contrast, the mutant \(\beta_{2d\_E7c\_F240L}\) led to faster, more pronounced inactivation compared to its corresponding WT (Fig. 5c). After 1000ms the currents of \(\beta_{2d\_WT}\), \(\beta_{2d\_G167S}\) and \(\beta_{2d\_S197F}\) showed a comparable extent of inactivation of 94±1%, 99±2% and 96±3% at 0mV test potential.

**Discussion**

The complex genetic principle of origin underlying ASD is still to be elucidated [40]. So far, genome-wide association and linkage
Table 2. Current and voltage parameters (mean ± SEM) of the constructs tested.

|                      | −β2d | β2d_WT | β2d_G167S | β2d_S197F | β2dE7c_WT | β2dE7c_F240L |
|----------------------|------|--------|-----------|-----------|-----------|-------------|
|                      | N=3  | N=9    | N=11      | N=8       | N=5       | N=5         |
| Peak Current Density (pA/pf) |      |        |           |           |           |             |
|                      | −1.2 | −51.6  | −72.3     | −68.1     | −17.8     | −21.1       |
|                      | ±1.0 | ±8.6   | ±10.3     | ±9.7      | ±5.8      | ±3.6        |
| V0.5act [mV]         | −11.5| −9.1   | −9.8      | −6.3      | −13.6     | −18.7       |
|                      | ±2.0 | ±1.2   | ±1.2      | ±2.5      | ±0.36     | ±2.5        |
| Steady-state Inactivation |      |        |           |           |           |             |
| V0.5inact [mV]       | −38.6| −47.9  | −35.7     | −33.3     | −28.2     |             |
|                      | ±1.8 | ±5.6   | ±3.7      | ±0.7      | ±1.9      |             |
| dv                   | 9.7  | 16.9*  | 13.5*     | 8.1       | 8.8       |             |
|                      | ±1.2 | ±2.9   | ±1.0      | ±1.5      | ±0.7      |             |

V0.5act, Voltage of half-maximal activation; V0.5inact, half-maximal inactivation voltage; dv, slope factor; −β2d, mock transfected cells; *indicates P<0.05 versus corresponding WT.

doi:10.1371/journal.pone.0095579.t002

...and incomplete voltage-dependent inactivation behavior are the biophysical hallmarks of the TS-mutation p.G406R in CACNA1C [2,17,39].

We observed a low penetrance of the three mutations in the ASD families under investigation, indicating the influence of other factors on the full expression of the condition. However, rare variants might contribute to the complex genetics and clinical heterogeneity of ASD. For comparison, an analogous sequencing approach studying CACNA1H as a candidate gene for ASD in 461 patients revealed six non-synonymous mutations in conserved domains, all showing a low penetrance and incomplete segregation [15]. Expression of complex genetic disorders depends on multiple factors, therefore a low penetrance of causal variants is quite common. Unaffected carriers might be subclinically affected, other risk factors might have contributed to the phenotype in the affected individuals, or the described mutations may only act as modifiers of the affected phenotype. Even for the Timothy syndrome - one of the most penetrant monogenic forms of autism - ASD has a penetrance of ~75% only [46].

The putative effects of the CaVβ2-mutations are ample as the β-subunit also plays an essential role as an interaction partner with intracellular signaling machineries. For instance, Krey et al. have recently demonstrated a new pathway involving the TS-mutation which leads to a calcium channel activity-dependent and conformation-dependent dendrite retraction via Gem-induced RhoA-signaling [18]. Here, the CaVβ-subunits might be involved in two ways: firstly they are known to regulate the channel activity, but secondly the interaction of CaV1.2 with Gem, mediated through the β-subunit is important for the ability of the channel to control activity-dependent dendritic arborization [18]. In summary, the role of the CaVβ2-subunit as a risk factor for ASD cannot only be attributed to its interaction with diverse ASD-associated pore-forming CaV1.2-subunits, but also because the CaVβ2-subunit acts as a signaling hub and can link together different ASD pathways.

The mutations presented here appear to follow a similar but milder mechanism of action that occurs in TS. TS presents with a multi-organ dysfunction, possibly indicating the consequences of a dramatic elevation of the intracellular calcium concentration. Mutations resulting in an even larger effect would likely abort the organism’s development [47]. Thus the mutation of the TS can be viewed as an extreme of the viable spectrum of mutations within the calcium signaling pathway. Compared to this, the mutations...
b2d_G167S, b2d_S197F and b2d_F240L exhibited rather moderate effects on channel gating that nonetheless might suffice to unbalance neuronal calcium channel function.

Because private and rare mutations seem to play a role in the predisposition to ASD [44], the discovery of rare variants with putative functional relevance might contribute to our understanding of the disorder’s etiology. Integrating the data from TS [2], the meta-analysis of psychiatric disorders [22], and functional studies on auxiliary β-subunits, we propose that inappropriate function of different components of the voltage-gated calcium channel complex can result in or may contribute to autism spectrum disorder. More detailed biophysical and cell-biological studies under physiological conditions are warranted for all such mutations.

Supporting Information

Table S1 All found variants in the exons and flanking intronic regions of CACNB2 in autistic patients.

(DOC)
Table S2 Current and voltage parameters (mean ± SEM) of the constructs tested. P-values stem from individual Student t-tests of the indicated channels.

Acknowledgments

We gratefully acknowledge the resources provided by the Autism Genetic Resource Exchange (AGRE) Consortium and the participating AGRE families. The Autism Genetic Resource Exchange is a program of Autism Speaks and is supported, in part, by grant 1U24MH080180 from the National Institute of Mental Health to Clara M. Laajecere [PJ]. We further acknowledge the Autism Tissue Program, New York Institute for Basic Research in Developmental Disabilities and Harvard Brain Tissue Resource Center for providing tissue-derived gDNA used in this study. Antonio M. Persico is acknowledged for providing the genomic DNA samples through the genomic DNA collection of the Autism Tissue Program. We are indebted to Prof. Dr. Heusch and Prof. Dr. Brodde, who kindly supplied gDNA from 259 population controls of West-European ancestry, to Dr. F. Lehmann-Horn for providing pcDNA3.1-Hygro-CACNA2D1 (Department of Applied Physiology, Ulm University, Germany) and to Dr. G. Varardi for providing us with HEK293-21c cells (stably expressing pore-forming (2C1c)subunits). We gratefully acknowledge the assistance by Dr. Wanchana Jangsangthong, Amika Hauser and Dr. Andreas Lazar.

Author Contributions

Conceived and designed the experiments: AFSB JM PN SH. Performed the experiments: AFSB RDN. Analyzed the data: AFSB PN SH. Contributed reagents/materials/analysis tools: JS GL PN SH. Wrote the paper: AFSB JM SH.

References

1. Centers for Disease Control and Prevention (2012) Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 61: 1–19.

2. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, et al. (2004) CaV1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119: 19–31.

3. Birnbaumer L, Qin N, Olesen R, Tarelius E, Platano D, et al. (1998) Structures and functions of calcium channel beta subunits. J Bioenerg Biomembr 30: 357–375.

4. Takahashi SX, Mittman S, Colecraft HM (2003) Distinctive modulatory effects of five human auxiliary beta2 subunit splice variants on L-type calcium channel gating. Biophys J 84: 3007–3021.

5. Ludwig A, Hockerz V, Hofmann F (1997) Regional expression and cellular localization of the alpha1 and beta subunit of high voltage-activated calcium channels in rat brain. J Neurosci 17: 1339–1349.

6. Jangsanngthong W, Kuzmenkina E, Khan IF, Mathies J, Hallin R, et al. (2009) Inactivation of L-type calcium channels is determined by the length of the N terminus of mutant beta1c subunits. Pflugers Arch 459: 399–411.

7. Cens T, Mangoni ME, Nargoz J, Charnet P (1996) Modulation of the alpha 1A Ca2+ channel by beta subunits at physiological Ca2+ concentration. FEBS Lett 391: 232–237.

8. Herzig S, Khan IF, Grandemann D, Mathies J, Ludwig A, et al. (2007) Mechanism of Ca(2+)2 channel modulation by the amino terminus of cardiac beta2-subunits. FASEB J 21: 1527–1538.

9. Jangsanngthong W, Kuzmenkina E, Khan IF, Mathies J, Hallin R, et al. (2010) Inactivation of L-type calcium channels is determined by the length of the N terminus of mutant beta1c subunits. Pflugers Arch 459: 399–411.

10. Buraei Z, Yang J (2010) The beta subunit of voltage-gated Ca2+ channels in rat brain. J Neurosci 17: 1339–1349.

11. Ercolano E, Fellenberg J, Hescheler J, Prince S, Magleby KL, et al. (2011) The beta subunit of the L-type calcium channel modulates the rate of inactivation of R-type calcium channel. J Biol Chem 287: 33470–33480.

12. Hara-Murphy A, Berjukov S, Hope CI, Dearden PK, Wurz SB, et al. (2005) A CACNAIF mutation identified in an X-linked retinal disorder shifts the voltage dependence of Cave4.1 channel activation. Proc Natl Acad Sci U S A 102: 7553–7558.

13. Strom SP, Stone JL, Ten Bosch JR, Merriman B, Cantor RM, et al. (2010) High-density SNP association study of the 17q21 chromosomal region linked to autism identifies CACNA1G as a novel candidate gene. Mol Psychiatry 15: 996–1005.

14. Splawski I, Yoo DS, Stutz SC, Cherry A, Clapham DE, et al. (2006) Novel functional properties of calcium channel beta subunits revealed by a genome-wide analysis. The Lancet 361: 1371–1379.

15. Lintas C, Alther I, Lombardi F, Sacco R, Persico AM (2010) Association of autism with polyomavirus infection in postmortem brains. J Neurovirol 16: 141–149.

16. Heczeg S, Khan IF, Grundemann D, Mathies J, Ludwig A, et al. (2007) Mechanism of Ca(2+)2 channel modulation by the amino terminus of cardiac beta2-subunits. FASEB J 21: 1527–1538.

17. Szabolcs P, Tamas G, Sirik J, Boroczki E, Bertai I, et al. (2004) A novel functional property of the beta subunit of the L-type calcium channel. J Biol Chem 279: 2056–2060.

18. Raisoja T, Ylä-Herttuala S, Heikkilä S, Suominen K, Glicksman Z, et al. (2004) L-type Ca2+ channel subunits modulate the rate of inactivation of R-type Ca2+ channel. J Biol Chem 279: 30243–30250.

19. Iossifov I, Zheng T, Baron M, Gilliam TC, Rzhetsky A (2008) Genetic-linkage mapping of complex hereditary disorders to a whole-genome molecular-network interaction genome. Nature Rev 18: 1130–1162.

20. Vosken SG, Day NG, McCormack AJ, Smith W, Craig PJ, et al. (1997) The expression of voltage-dependent calcium channel beta subunits in human cerebellum. Neuroscience 80: 161–174.
41. Folstein SE, Rosen-Sheidley B (2001) Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2: 943–955.
42. Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, et al. (2012) Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet 8: e1002521.
43. Abrahams BS, Geschwind DH (2008) Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 9: 341–355.
44. Ben-David E, Shifman S (2012) Networks of neuronal genes affected by common and rare variants in autism spectrum disorders. PLoS Genet 8: e1002556.
45. Skafidas E, Testa R, Zantomio D, Chana G, Everall IP, et al. (Sept 11, 2012) Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Mol Psychiatry: 10.1038/mp.2012.1126.
46. Bader PL, Fazio M, Kim LH, Owen SF, Tadross MR, et al. (2011) Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc Natl Acad Sci U S A 108: 15432–15437.
47. Liao P, Soong TW (2010) CaV1.2 channelopathies: from arrhythmias to autism, bipolar disorder, and immunodeficiency. Pfluigers Arch 460: 353–359.